Literature DB >> 22639237

Interleukin-18 levels reflect the long-term prognosis of acute lung injury and acute respiratory distress syndrome.

Hideyuki Makabe1, Masahiro Kojika, Gaku Takahashi, Naoya Matsumoto, Shigehiro Shibata, Yasushi Suzuki, Yoshihiro Inoue, Shigeatsu Endo.   

Abstract

PURPOSE: The purpose of this study was to investigate the relationship between the blood levels of interleukin (IL)-18 measured in the early stage of acute respiratory failure and the prognosis for patient survival.
METHODS: The study subjects were 38 patients with acute respiratory failure treated at our institution during the 4-year period from April 2004 to March 2008. The underlying clinical condition was defined as acute respiratory distress syndrome (ARDS; n = 12) or acute lung injury (ALI; n = 26). The serum levels of interleukin (IL)-18, IL-12, and tumor necrosis factor (TNF)-α were measured by enzyme-linked immunosorbent assays.
RESULTS: The ARDS group showed significantly higher serum levels of IL-18, IL-12, and TNF-α even at an early stage after disease onset compared with the ALI group. A negative correlation was noted between the PaO(2)/FIO(2) ratio (P/F ratio) and serum IL-18 level. Analysis of all 38 patients with ALI/ARDS revealed a 30-day mortality rate of 7.9 %, 60-day mortality rate of 15.8 %, and 90-day mortality rate of 18.4 %. The early-stage serum levels of IL-18, IL-12, and TNF-α were significantly higher in the non-survivors at 60 and 90 days, but not at 30 days, than in the corresponding survivors.
CONCLUSION: The present data demonstrate an inverse correlation between serum IL-18 level and the P/F ratio, suggesting the possible involvement of IL-18 in the pathogenesis of respiratory failure in patients with ALI/ARDS. Early-stage serum IL-18, IL-12, and TNF-α levels appear to reflect the >60-day prognosis in patients with ALI/ARDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22639237     DOI: 10.1007/s00540-012-1409-3

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  17 in total

1.  Interleukin 18 (IL-18) levels in patients with sepsis.

Authors:  S Endo; K Inada; Y Yamada; G Wakabayashi; H Ishikura; T Tanaka; S Sato
Journal:  J Med       Date:  2000

Review 2.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

3.  IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.

Authors:  H Tsutsui; K Nakanishi; K Matsui; K Higashino; H Okamura; Y Miyazawa; K Kaneda
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

4.  Purification of a factor which provides a costimulatory signal for gamma interferon production.

Authors:  K Nakamura; H Okamura; K Nagata; T Komatsu; T Tamura
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

5.  Increased serum and hepatic tissue levels of interleukin-18 in patients with fulminant hepatic failure.

Authors:  Masahiro Shinoda; Go Wakabayashi; Motohide Shimazu; Hidetsugu Saito; Ken Hoshino; Minoru Tanabe; Yasuhide Morikawa; Shigeatsu Endo; Hiromasa Ishii; Masaki Kitajima
Journal:  J Gastroenterol Hepatol       Date:  2006-11       Impact factor: 4.029

6.  Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells.

Authors:  A J Puren; G Fantuzzi; Y Gu; M S Su; C A Dinarello
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

7.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher
Journal:  Crit Care Med       Date:  1998-11       Impact factor: 7.598

9.  Interleukin 18 levels reflect the severity of acute pancreatitis.

Authors:  S Endo; Y Inoue; Y Fujino; G Wakabayashi; K Inada; S Sato
Journal:  Res Commun Mol Pathol Pharmacol       Date:  2001

10.  Endotoxin-induced pulmonary leukostasis in the rat: role of platelet-activating factor and tumor necrosis factor.

Authors:  S W Chang
Journal:  J Lab Clin Med       Date:  1994-01
View more
  21 in total

1.  Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting Its Ubiquitination and Degradation Mediated by the SCFFBXL2 E3 Ligase.

Authors:  SeungHye Han; Travis B Lear; Jacob A Jerome; Shristi Rajbhandari; Courtney A Snavely; Dexter L Gulick; Kevin F Gibson; Chunbin Zou; Bill B Chen; Rama K Mallampalli
Journal:  J Biol Chem       Date:  2015-06-02       Impact factor: 5.157

2.  CORM-2 inhibits TXNIP/NLRP3 inflammasome pathway in LPS-induced acute lung injury.

Authors:  Lei Jiang; Dongsheng Fei; Rui Gong; Wei Yang; Wei Yu; Shangha Pan; Mingran Zhao; Mingyan Zhao
Journal:  Inflamm Res       Date:  2016-07-13       Impact factor: 4.575

Review 3.  The Basic Science and Molecular Mechanisms of Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Paola Aranda-Valderrama; Ata Murat Kaynar
Journal:  Int Anesthesiol Clin       Date:  2018

4.  Critical role for the NLRP3 inflammasome during acute lung injury.

Authors:  Jamison J Grailer; Bethany A Canning; Miriam Kalbitz; Mikel D Haggadone; Rasika M Dhond; Anuska V Andjelkovic; Firas S Zetoune; Peter A Ward
Journal:  J Immunol       Date:  2014-05-02       Impact factor: 5.422

Review 5.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

6.  The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.

Authors:  Shima Makaremi; Ali Asgarzadeh; Hamed Kianfar; Alireza Mohammadnia; Vahid Asghariazar; Elham Safarzadeh
Journal:  Inflamm Res       Date:  2022-06-25       Impact factor: 6.986

Review 7.  The amount of cytokine-release defines different shades of Sars-Cov2 infection.

Authors:  S Bindoli; M Felicetti; P Sfriso; A Doria
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-28

8.  Isoflurane attenuates lipopolysaccharide-induced acute lung injury by inhibiting ROS-mediated NLRP3 inflammasome activation.

Authors:  Ning Yin; Zhendan Peng; Bin Li; Jiangyan Xia; Zhen Wang; Jing Yuan; Lei Fang; Xinjiang Lu
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

9.  Risk factors for outcomes of acute respiratory distress syndrome patients: a retrospective study.

Authors:  Qingqing Dai; Sicong Wang; Ruijin Liu; Hongliang Wang; Junbo Zheng; Kaijiang Yu
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

10.  Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury.

Authors:  Konrad Peukert; Mario Fox; Susanne Schulz; Caroline Feuerborn; Stilla Frede; Christian Putensen; Hermann Wrigge; Beate Mareike Kümmerer; Sascha David; Benjamin Seeliger; Tobias Welte; Eicke Latz; Dennis Klinman; Christoph Wilhelm; Folkert Steinhagen; Christian Bode
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.